Betsy's Note: Patient-reported outcomes capture what traditional safety and efficacy endpoints cannot: how patients experience their disease and its treatment in daily life. That evidence is central to market access, guideline inclusion, and long-term brand defense.

‍

EXECUTIVE SUMMARY

Patient-reported outcomes (PROs) are one of the most underused tools in commercial life sciences. They capture something traditional endpoints cannot: what it is actually like for patients to live with a disease and its treatment. That perspective can shape formulary decisions, guideline inclusion, outcomes-based contracts, and long-term brand defense. Yet too few evidence plans treat PRO data as a commercial priority. Companies that build PRO strategy into their evidence plan early are winning durable commercial advantage.

‍Show real value in the market

PRO data that appears in the label can be promoted by sales. This alone is reason enough to invest. The longer-term play is broader. PRO data published in journals, presented at congresses, and woven into AMCP dossiers and HTA filings builds a value story that goes well beyond what the label alone can carry. It gives payers, formulary boards, and guideline bodies evidence they can act on even when a formal label claim does not exist.

The real power of PRO data is in showing the full picture of patient value. Traditional endpoints measure whether a therapy works. PRO data measures what that means for the person taking it: symptom burden, physical function, productivity, activities of daily living, quality of life. This is the holistic view that turns a clinical profile into a value story.

‍

Where PRO data drives decisions

For HTA filings, PRO-derived utility values feed directly into economic analyses. Published PRO data also supports the broader case around unmet need and treatment burden that HTA bodies weigh when forming their views on clinical relevance. In formulary reviews, PRO evidence showing real-world patient benefit strengthens the case for preferred placement and favorable coverage terms.

After launch, the demands grow. Outcomes-based contracts need defined endpoints, named data sources, and a way to track patients, all running before the first script is written. AMCP dossiers gain strength from patient data that goes beyond the trial population. Formulary renewals, usually due two to three years after first listing, need long-term outcomes data. That data either starts building from day one of launch or it will not exist when the renewal comes due.

The evidence plan that wins access is designed in parallel with clinical development, with payer and HTA needs built into the integrated evidence generation plan and target product profile from the start. Closing evidence gaps after approval is too late.

‍

Build PRO strategy in parallel with clinical development

The strongest PRO plans are built in parallel with clinical development. The integrated evidence generation plan and target product profile should define what PRO data is needed, who will use it, and how it will be collected across the full lifecycle. PROs are becoming the most impactful differentiator to competing therapies.

Burden-of-illness studies and natural history research, run during pre-IND or early development, record the current treatment burden from the patient's view: how often symptoms hit, how severe they are, how they disrupt daily life, what makes patients stop taking their medicine, and where the care pathway breaks down. This evidence frames the unmet need in patient terms, which is how payers and guideline bodies weigh value.

Patient preference studies use methods like conjoint analysis or discrete choice experiments to measure what patients want in a new therapy versus what they have now. The tradeoffs they capture (side effects versus how well it works, dosing ease, how the drug is given, impact on daily life) show whether a product profile will stand apart. Across a portfolio, they help decide which disease area to pursue first when several options are competing for investment.

If the goal includes a label-grade PRO claim, the bar is higher. The instrument must be validated for the target population. The study design must match agency guidance. The clinical meaning of the score change must be proven. That work takes time, and it needs to start in early development.

Qualitative research adds what numbers alone cannot. Patient interviews, caregiver studies, and advisory boards reveal how treatment burden is lived: the fatigue that builds over a long course of treatment, the lost workdays, the coping methods patients use that their doctor rarely sees. This evidence gives payers the context that makes the numbers meaningful.

‍

COMING SOON: Don't neglect HCPs in your evidence strategy

Access strategy tends to focus on what payers require. That focus is necessary, but it misses a critical link in the chain: clinical guidelines are the top source payers use to evaluate coverage decisions, and medical experts are the ones who write them. The product's place in the treatment landscape, and the unmet need it fills, has to be shaped by understanding where awareness gaps exist among physicians and filling those gaps with evidence in parallel with the clinical development plan. More on this in an upcoming post.

‍

Three questions to build into the evidence plan

First: what is the patient experience today, and where are the gaps? The unmet need case is sharper when it rests on what patients report, not just what clinical data implies. Knowing where the current standard of care falls short from the patient's view is the base of a strong value story.

Second: what will the access and adoption strategy need? This goes beyond payer evidence gaps. It includes the data needed for clinical guideline inclusion, the evidence that will support field teams in formulary talks, and the comparative claims that will shape prescriber choice.

Third: will a PRO be part of the diagnosis, treatment plan, or ongoing monitoring? PRO tools can play a role in open-label extensions, patient selection, treatment response tracking, and real-world evidence. Defining that role early shapes which tools to use, how to collect the data, and where it fits in the care pathway.

These are choices that belong in the integrated evidence generation plan. Building PRO strategy into the development timeline from the start is how patient-reported data becomes a lasting commercial edge.

‍‍ ---

Betsy J. Lahue is CEO of Alkemi, a life sciences consulting firm specializing in HEOR, Market Access, and Market Shaping.

Alkemi has contributed to launches representing tens of billions in global sales and partners with life sciences executives to build evidence, value and access strategies that translate clinical innovation into real-world adoption. To discuss your program, contact us at www.alkemihealth.com/contact